Amgen, Inc. (AMGN) Updates FY12 Earnings Guidance
Amgen, Inc. (AMGN) updated its FY12 earnings guidance on Tuesday. The company provided EPS guidance of $6.50-6.60 for the period.
A number of research firms have also recently commented on AMGN. Analysts at Deutsche Bank upgraded shares of Amgen from a hold rating to a buy rating in a research note to investors on Monday. They now have a $108.00 price target on the stock. On a related note, analysts at RBC Capital reiterated an outperform rating on shares of Amgen in a research note to investors on Thursday, October 4th. They now have a $90.00 price target on the stock. Finally, analysts at Cowen reiterated an outperform rating on shares of Amgen in a research note to investors on Monday, October 1st.
Amgen, Inc. (AMGN) traded down 0.55% on Tuesday, hitting $87.32. Amgen, Inc. (AMGN) has a 52-week low of $54.59 and a 52-week high of $89.95. The company has a market cap of $67.303 billion and a price-to-earnings ratio of 19.22.
Amgen last posted its quarterly earnings results on Tuesday, October 23rd. The company reported $1.67 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.47 by $0.20. The company’s quarterly revenue was up 9.5% on a year-over-year basis. Analysts expect that Amgen, Inc. (AMGN) will post $6.35 EPS for the current fiscal year.
Amgen Inc. (Amgen) is a biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for illnesses.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.